Tardive dyskinesia (TD) is a movement disorder caused by certain medications, most commonly antipsychotics. It produces involuntary, repetitive movements of the face, tongue, jaw, and sometimes the limbs or trunk. The movements are irregular and purposeless, like lip smacking, tongue darting, or finger writhing, and they can persist even after the medication that caused them is stopped. TD affects roughly 1 to 2 percent of people taking antipsychotics in a given year, though rates vary widely depending on the drug, dose, and duration of use.
What TD Looks and Feels Like
The most recognizable signs involve the lower face and mouth. People with TD may purse or pucker their lips, chew without food in their mouth, push their tongue in and out, or grimace repeatedly. These movements aren’t under the person’s control. In some cases, the arms and legs are also affected, producing slow, writhing finger movements sometimes described as “piano-playing” fingers, or rocking of the trunk. In more severe presentations, the muscles involved in swallowing and breathing can be affected, which creates functional problems beyond the visible movements.
The DSM-5 defines TD as involuntary writhing or dance-like movements, generally of the tongue, lower face, jaw, and extremities, that develop after using a dopamine-blocking medication for at least a few months. Symptoms must last at least a few weeks to meet the diagnostic threshold. Critically, TD persists for at least a month after the offending drug is discontinued, which is what separates it from movement side effects that resolve quickly when the medication changes.
Which Medications Cause It
The primary culprits are antipsychotic drugs, both older (first-generation) and newer (second-generation) types. Older antipsychotics carry a higher risk, but second-generation antipsychotics are not risk-free. In one large study of TD patients, nearly 80 percent were taking newer antipsychotics at the time of diagnosis, reflecting how widely these drugs are now prescribed.
Two anti-nausea medications, metoclopramide and prochlorperazine, also cause TD. Metoclopramide carries an FDA black box warning for this reason: treatment can cause “a potentially irreversible and disfiguring disorder characterized by involuntary movements of the face, tongue, or extremities.” The risk climbs sharply when metoclopramide is used for 12 weeks or longer, in people over 65, in women, and in people with diabetes. Antidepressants cause TD far less commonly, but when they do, it tends to appear in older adults.
Why It Happens in the Brain
All of the drugs linked to TD share one thing in common: they block dopamine receptors in the brain, specifically a type called D2 receptors. Dopamine is a chemical messenger involved in coordinating movement. When a medication blocks these receptors for months or years, the brain compensates by becoming more sensitive to whatever dopamine is still available. This is sometimes called dopamine supersensitivity.
The result is a kind of overreaction in the brain’s movement control circuits. The areas most affected are deep brain structures that normally fine-tune voluntary movement. Once those circuits have been rewired by long-term dopamine blockade, the abnormal movements can take on a life of their own. This also explains a frustrating paradox: when the antipsychotic dose is lowered, TD symptoms sometimes get temporarily worse, because the hypersensitive receptors are suddenly exposed to more dopamine without the drug dampening the signal.
Who Is Most at Risk
Age is the single strongest risk factor. Risk begins climbing after 40 and is highest in adults over 65, likely because of age-related changes in how the brain processes dopamine. Some older adults develop TD even after relatively short courses of medication.
Women face a somewhat higher risk than men. One study found that postmenopausal women developed TD at rates as high as 30 percent after about a year of antipsychotic use. Black Americans develop TD more frequently than white Americans, while people of Filipino and Asian descent appear to have a lower risk. Having bipolar disorder also raises your odds compared with other people taking the same medications.
How It Differs From Other Movement Side Effects
Several other movement problems can result from the same medications, and they sometimes look similar enough to cause confusion.
- Akathisia is a feeling of inner restlessness and an inability to sit still. Unlike TD, the core experience is subjective discomfort and an urge to move, not involuntary movements you can’t control.
- Dystonia involves sustained muscle contractions that pull the body into abnormal postures, like a twisted neck or clenched jaw. TD movements are irregular and non-sustained rather than fixed postures.
- Drug-induced parkinsonism looks like the opposite of TD: slowness, stiffness, and a rhythmic resting tremor. TD is a hyperkinetic disorder (too much movement), while parkinsonism is hypokinetic (too little).
Timing also helps distinguish these conditions. Dystonia and parkinsonism typically appear within hours to weeks of starting a medication and often improve when the drug is reduced. TD develops after months to years of exposure and persists or worsens when the medication is lowered.
How Clinicians Monitor for It
The standard monitoring tool is the Abnormal Involuntary Movement Scale (AIMS), a 12-item assessment that checks for involuntary movements across seven body regions. Each region is scored from 0 (no abnormal movement) to 4 (severe, persistent movement at maximum amplitude). Additional items assess the person’s overall severity and dental status, since mouth and jaw movements can affect teeth and oral health over time. Regular AIMS screening is recommended for anyone on long-term antipsychotic therapy, though in practice this screening is often inconsistent.
Treatment and Management
The first question clinicians ask is whether the medication causing TD can be safely stopped. For people who don’t have a psychotic disorder, slowly tapering the drug over weeks to months is sometimes possible. But for most people with schizophrenia or other serious mental illness, stopping the antipsychotic would risk a relapse that could be worse than the movement disorder itself.
When the antipsychotic can’t be discontinued, switching to a drug with weaker dopamine-blocking activity may help. Medications like clozapine and quetiapine have lower affinity for D2 receptors and are associated with less TD risk. Keeping the dose at the low end of the effective range throughout treatment is also recommended to limit ongoing risk. One thing clinicians avoid is raising the antipsychotic dose to mask TD symptoms. While higher doses can temporarily suppress the movements, this approach worsens the underlying problem over time.
Two medications are FDA-approved specifically for treating TD. Both belong to a class called VMAT2 inhibitors (valbenazine and deutetrabenazine), which work by reducing the amount of dopamine available for release in the brain’s movement circuits. A third drug in the same class, tetrabenazine, is sometimes used off-label. These medications don’t cure TD, but they can meaningfully reduce the severity of involuntary movements for many people.
Patients starting treatment should know that symptoms can temporarily worsen during medication adjustments, a phenomenon called withdrawal emergent dyskinesia. This flare usually settles over time but can be alarming if you’re not expecting it.